HSP90AA1 and breast cancer: In breast cancer, preclinical studies have demonstrated sensitivity of HER2+ tumors to HSP90 inhibitor [2-4], lately though it was demonstrated that HSP90 is a very effective target of therapy in triple negative breast cancers [5,6].